SLSN

Business Context and Reporting Period

Company: Nanophase Technologies Corporation (trading symbol: NANX), a smaller reporting company focused on beauty and life-science markets through its Solésence subsidiary and advanced materials divisions.

Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2024.

Business Overview: The company manufactures engineered materials and finished prestige skin care products. Key growth drivers include Solésence finished products and Active Pharmaceutical Ingredients (APIs) for sunscreens. Legacy markets include architectural coatings and medical diagnostics, though demand for diagnostics has decreased.

Key Financial Metrics

Note: Debt figures exclude operating lease obligations. Related party debt includes lines of credit and term loans from Beachcorp, LLC and Strandler, LLC.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9.9% year-over-year (YoY) for the quarter and 7.4% YoY for the six-month period. This was driven by a 44% increase in Solésence product revenue, partially offset by a decline in Personal Care Ingredients sales.
• Profitability: The company returned to profitability, reporting net income of $856,000 for the quarter compared to $333,000 in the prior year quarter. For the six months, net income was $1.747 million compared to a net loss of $825,000 in the prior year.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly (13% for the quarter, 20% for six months) primarily due to reduced legal costs following the resolution of litigation with BASF.
• Capital Structure: In Q2 2024, the company issued Series X Preferred Stock for $6 million, which was subsequently converted into 15 million shares of common stock. This increased total shareholders' equity from $1.9 million at year-end 2023 to $11.9 million.
• Cash Flow: Net cash used in operating activities increased to $4.42 million for the six months ended June 30, 2024, compared to $1.96 million in the prior year, driven by increased inventory levels and accounts receivable.

Outlook, Risks, and Contingencies

• Capital Expenditures: Management expects capital spending for 2024 to range between $3 million and $6 million to expand manufacturing capacity, funded by operations and existing credit facilities.
• BASF Litigation Resolution: A long-standing dispute with BASF regarding exclusivity rights for zinc oxide was settled in April 2024. The settlement allows the company to sell finished products containing zinc oxide through Solésence globally while maintaining BASF's exclusivity for raw ingredient sales in specific fields. The risk of forced equipment sale to BASF remains if performance requirements are not met.
• Debt Maturity: Key related-party loan agreements with Beachcorp, LLC and Strandler, LLC are set to expire on October 1, 2025. Failure to refinance or extend these agreements poses an operating risk.
• Customer Concentration: The top four customers accounted for 60% of revenue in Q2 2024 and 62% for the six-month period. Loss of a major customer could materially impact operations.
• Margin Pressure: Gross margins may be impacted by raw material costs (e.g., rare earth elements, zinc) and wage inflation, though the company aims to pass these costs through to customers.

Investor Verification Checklist

• Debt Renewal: Verify the status of refinancing for related-party debt maturing in October 2025.
• Inventory Levels: Review the $13.9 million inventory balance and the $1.6 million reserve to assess obsolescence risks given the shift in demand from diagnostics to beauty products.
• BASF Agreement Terms: Confirm ongoing compliance with the amended exclusivity terms to avoid triggering equipment sale clauses.
• Customer Concentration: Monitor the stability of the top four customers, which represent the majority of revenue.
• Cash Burn: Assess the sustainability of operating cash outflows ($4.4M for six months) against current cash reserves ($2.4M) and financing capacity.